9-[(2-bromo-4-isopropyl)-phenyl]-6-chloro-2-methyl-7-hydropurin-8-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 9-[(2-bromo-4-isopropyl)-phenyl]-6-chloro-2-methyl-7-hydropurin-8-one
• 英文别名: 9-(2-bromo-4-propan-2-ylphenyl)-6-chloro-2-methyl-7H-purin-8-one
• 化学式: C₁₅H₁₄BrClN₄O
• 分子量: 381.659
• InChiKey: KIEIYFMDIQYRQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-[(2-bromo-4-isopropyl)-phenyl]-6-chloro-2-methyl-7-hydropurin-8-one 在 三氯氧磷 作用下， 反应 108.0h， 生成 [9-(2-Bromo-4-isopropyl-phenyl)-8-chloro-2-methyl-9H-purin-6-yl]-butyl-ethyl-amine
  参考文献：
  名称：

  Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists

  摘要：

  A series of purin-8-ones was prepared and discovered to have excellent binding affintity to the CRH-R1 receptor. Structure-activity studies focused on amine side-chain optimization, urea substitution and pyridyl isostere incorporation. Thus, the highly potent purin-8-ones show promise as a new class of potential anxiolytics and/or antidepressants. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science I,td. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00108-0
• 作为产物：
  描述：

  2-甲基-4,6-二羟基嘧啶 在 硝酸 、 铁粉 、 溶剂黄146 、 N,N-二乙基苯胺 、 三氯氧磷 作用下， 以 甲醇 、 二甲基亚砜 、 甲苯 为溶剂， 反应 29.0h， 生成 9-[(2-bromo-4-isopropyl)-phenyl]-6-chloro-2-methyl-7-hydropurin-8-one
  参考文献：
  名称：

  Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists

  摘要：

  A series of purin-8-ones was prepared and discovered to have excellent binding affintity to the CRH-R1 receptor. Structure-activity studies focused on amine side-chain optimization, urea substitution and pyridyl isostere incorporation. Thus, the highly potent purin-8-ones show promise as a new class of potential anxiolytics and/or antidepressants. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science I,td. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00108-0

文献信息

• Certain alkylene diamine-substituted heterocycles
  申请人：Neurogen Corporation

  公开号：US06506762B1

  公开（公告）日：2003-01-14

  The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY1 receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula I-XV. wherein X is N or CR14; W is S, O, or NR15; Y is N or CR3; E, F, and G are each, independently, CR3 or N; I and J are each, independently, C═O, S, O, CR3R16 or NR15 when single bonded to both adjacent ring atoms, or N, or CR3 when double bonded to an adjacent ring atom; K is N or CR3 when double bonded to L or J, or O, S, C═O, CR3R16, or NR15 when single bonded to both adjacent ring atoms, or N or CR3 when double bonded to an adjacent ring atom; L is N or CR16 when single bonded to all atoms to which it is attached, or C (carbon) when double bonded to K; the 6- or 7-membered ring that contains I, J, K, and L may contain from 1 to 3 double bonds, from 0 to 2 heteroatoms, and from 0 to 2 C═O groups, wherein the carbon atom of such groups are part of the ring and the oxygen atom is a substituent on the ring; Q is O or NR15. Such compounds inhibit the activity of neuropeptide Y at those receptors are useful in treating physiological disorders associated with an excess of neuropeptide Y, including eating disorders, such as, for example, obesity and bulimia, and certain cardiovascular diseases, for example, hypertension.

  本发明还提供了一种通用方法，通过该方法可以修改单环、双环或三环杂环化合物，从而获得在NPY1受体上具有强效拮抗作用的化合物。本发明提供了NPY受体的新颖、强效、非肽类拮抗剂，特别是NPY1受体，这些拮抗剂是设计自一系列单环、双环或三环杂环核心。本发明涉及用于治疗与神经肽Y过量有关的生理紊乱的新化合物、组合物和方法。本发明涵盖的新型化合物符合以下公式I-XV。其中X为N或CR14；W为S、O或NR15；Y为N或CR3；E、F和G分别独立地为CR3或N；I和J分别独立地为C═O、S、O、CR3R16或NR15（当与两个相邻环原子形成单键时），或N或CR3（当与一个相邻环原子形成双键时）；K为N或CR3（当与L或J形成双键时），或O、S、C═O、CR3R16或NR15（当与两个相邻环原子形成单键时），或N或CR3（当与一个相邻环原子形成双键时）；L为N或CR16（当与所有相邻原子形成单键时），或C（碳）（当与K形成双键时）；包含I、J、K和L的6-或7-成员环可包含1至3个双键，0至2个杂原子和0至2个C═O基团，其中该基团的碳原子是环的一部分，氧原子是环上的取代基；Q为O或NR15。这些化合物抑制神经肽Y在这些受体上的活性，对于治疗与神经肽Y过量有关的生理紊乱，包括饮食紊乱，例如肥胖症和暴食症，以及某些心血管疾病，例如高血压，具有用处。
• CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES
  申请人：NEUROGEN CORPORATION

  公开号：EP1224187A2

  公开（公告）日：2002-07-24
• US6506762B1
  申请人：——

  公开号：US6506762B1

  公开（公告）日：2003-01-14
• US6696445B2
  申请人：——

  公开号：US6696445B2

  公开（公告）日：2004-02-24
• US7074929B2
  申请人：——

  公开号：US7074929B2

  公开（公告）日：2006-07-11